SCHEMBL5535940

SCHEMBL5535940

Fc1ccc(CN[CH]c2ccccc2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.47
HTT P42858 2/20 0.40
MAOB P27338 2/20 0.38
PPARG P37231 1/20 0.37
PIM1 P11309 1/20 0.37
HDAC4 P56524 1/20 0.36
MEF2D Q14814 1/20 0.36
ADH1B P00325 1/20 0.36
ADH1C P00326 1/20 0.36
ADH1A P07327 1/20 0.36
ADH7 P40394 1/20 0.36
NFE2L2 Q16236 1/20 0.36
P2RX7 Q99572 1/20 0.36
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
MAOA P21397 1/20 0.35
NTRK1 P04629 1/20 0.35
S1PR3 Q99500 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539432 0.85 MMP13 (0.42) KDM1AADH1BADH1CADH1AADH7
SCHEMBL5545050 0.85 MAPT (0.38) KDM1AMAOBPPARGADH1BADH1C
SCHEMBL5534775 0.84 EGFR (0.40) KDM1AMAOBADH1BADH1CADH1A
SCHEMBL5534736 0.80 PLA2G1B (0.49) KDM1AMAOBADH1BADH1CADH1A
SCHEMBL5536817 0.79 NFE2L2 (0.47) KDM1AMAOBNFE2L2MAOA
SCHEMBL5540801 0.79 CCNE2 (0.38) KDM1AMAOBADH1BADH1CADH1A
SCHEMBL7385255 0.77 ADH1B (0.58) ADH1BADH1CADH1AADH7MAOA
SCHEMBL5539505 0.77 LMNA (0.50) KDM1AMAOBADH1BADH1CADH1A
SCHEMBL5544373 0.76 PLA2G1B (0.47) ALDH1A1
SCHEMBL5539358 0.76 CHRM2 (0.49) HTTGRIN1GRIN2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM1A 4622/4885HTT 4644/4885MAOB 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.